Therachon Moves 'Academic Prototype' Towards Clinic

 
• By Lubna Ahmed

Emerging Company Profile: Switzerland-based Therachon is developing therapeutics for rare genetic pediatric diseases with a lead program in achondroplasia, also known as genetic dwarfism. CEO Luca Santarelli explains the mechanism behind lead molecule TA-46 and plans moving forward.

Emerging Company Profile Regular column feature image Version 2
Therachon CEO discusses achondroplasia program

More from Start-Ups & SMEs

More from Business